Topic: cell manufacturing
iBio, a CDMO that focuses on plant-based biotechnology, said it reached an agreement to support Aethlon Medical with the production of its blood purification device.
Swiss CDMO Lonza said it has purchased a clinical-stage manufacturing site in Hayward, California, from Shire.
Japan's Fujifilm Diosynth Biotechnologies has completed a $9 million expansion project of its cell manufacturing facilities in the U.K.
Kite Pharma's ability to handle the complex manufacturing of its CAR-T cancer treatment is one reason Gilead is paying $11.9 billion for the company.
Bristol-Myers Squibb is selling a clinical materials manufacturing facility in Washington to Seattle Genetics, which will keep the 72 workers.
Oxford BioMedica has a new deal for up to $100 million to provide the lentiviral vectors for the personalized CAR-T treatment Novartis is developing.
Seqirus said it has achieved an industry first by producing a cell-based influenza vaccine on a commercial scale using a virus grown in cells.
Lonza, which is dealing with FDA concerns about its cell manufacturing facility in the U.S., has acquired a gene and cell CMO in Europe.
Swiss CDMO Lonza, which has run into FDA concerns about its FDA operations before, has had its cell therapy facility in the U.S. slapped with a warning letter.
Argentina's Sinergium Biotech, which is in a consortium to develop a Zika virus vaccine, intends to build a new plant that will use cell biology that can be utilized for a Zika vaccine or for the flu vaccine production it already does.